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Abstract
Background
It is important to have methods available to estimate the number of people who have undi-
agnosed HIV and are in need of antiretroviral therapy (ART).
Methods
The method uses the concept that a predictable level of occurrence of AIDS or other HIV-re-
lated clinical symptoms which lead to presentation for care, and hence diagnosis of HIV,
arises in undiagnosed people with a given CD4 count. The method requires surveillance
data on numbers of new HIV diagnoses with HIV-related symptoms, and the CD4 count at
diagnosis. The CD4 count-specific rate at which HIV-related symptoms develop are esti-
mated from cohort data. 95% confidence intervals can be constructed using a simple
simulation method.
Results
For example, if there were 13 HIV diagnoses with HIV-related symptoms made in one year
with CD4 count at diagnosis between 150–199 cells/mm3, then since the CD4 count-spe-
cific rate of HIV-related symptoms is estimated as 0.216 per person-year, the estimated
number of person years lived in people with undiagnosed HIV with CD4 count 150–199
cells/mm3 is 13/0.216 = 60 (95% confidence interval: 29–100), which is considered an
estimate of the number of people living with undiagnosed HIV in this CD4 count stratum.
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Conclusions
The method is straightforward to implement within a short period once a surveillance system
of all new HIV diagnoses, collecting data on HIV-related symptoms at diagnosis, is in place
and is most suitable for estimating the number of undiagnosed people with CD4 count
<200 cells/mm3 due to the low rate of developing HIV-related symptoms at higher CD4
counts. A potential source of bias is under-diagnosis and under-reporting of diagnoses with
HIV-related symptoms. Although this method has limitations as with all approaches, it is im-
portant for prompting increased efforts to identify undiagnosed people, particularly those
with low CD4 count, and for informing levels of unmet need for ART.
Introduction
Estimates of the number of people in a country or region who have undiagnosed HIV are im-
portant as they may prompt increased efforts to identify and treat such people, and may inform
plans for the future delivery of antiretroviral therapy (ART). It is of particular importance to
estimate the number of people with undiagnosed HIV who have a low CD4 count (below
350 cells/mm3, but especially below 200 cells/mm3) as treatment guidelines state that ART
should be started without delay in such people, due to the risk of clinical disease [1].
Various methods have been used to estimate the number of people living with HIV in a par-
ticular region or country [2]. These include methods that make use of HIV prevalence survey
data [3–5] and methods that apply “back-calculation” techniques to case reporting data on
HIV/AIDS diagnoses [6–10]. While generally designed to estimate the overall number of peo-
ple with HIV, these methods can also be used specifically to estimate the number of people
with undiagnosed HIV. Although these methods have many advantages, they also have some
limitations. Prevalence survey-based methods are not always straightforward to perform or in-
terpret, especially when they are used to understand the CD4 count profile of a population.
Back-calculation methods are often statistically complex and require reliable information on
diagnoses and deaths in people with HIV in all preceding years.
In this paper, we describe an additional alternative method to estimate the number of people
living with undiagnosed HIV with low CD4 count.
Method
The method is based on the assumption that people with undiagnosed HIV who develop AIDS
or other HIV-related symptoms of sufficient severity, or which are sufficiently specific to HIV,
will present for care and be diagnosed with HIV as a result. This is essentially the same princi-
ple on which original back-calculation methods were based [11,12]. We will refer to these
HIV-related symptoms which are likely to lead to presentation for care and HIV diagnosis sim-
ply as “HIV-related symptoms”. Such symptoms would typically refer to those listed among
category B and C conditions (CDC-B and -C events) in the 1993 revised CDC classification
system [13]. Only symptoms which are assumed to be caused by HIV are of interest, so symp-
toms related to a bacterial sexually transmitted infection, for example, should not count.
The data which are required for this method include data on the number of HIV diagnoses
for which presence of HIV-related symptoms was a reason for the HIV test leading to diagnosis
and the CD4 count at the time of diagnosis. It should be noted that these data requirements do
not mean that all new diagnoses need to be specifically investigated for HIV-related symptoms
(such as by additional physical examination), so collection of such information on all new HIV
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diagnoses should be feasible in any setting. Further, HIV diagnoses that are made due to symp-
toms of primary HIV infection should not be included.
The main concepts of the method are demonstrated in Fig. 1 using the CD4 count stratum
<200 cells/mm3 and are described as follows. The number of people who are diagnosed with
HIV with HIV-related symptoms in a given CD4 count stratum over a specified period of time
represents a proportion of the total undiagnosed population with CD4 count in that stratum. The
size of the proportion is determined by the CD4 count-specific rate of such symptoms. Our meth-
od then reverses this logic: for each CD4 count stratum, the number of person-years lived with
undiagnosed HIV is obtained by dividing the number of HIV diagnoses with HIV-related symp-
toms over a given period of time by the CD4 count-specific rate of HIV-related symptoms for
that stratum.We thus consider this an estimate of the number of people living with undiagnosed
HIV in the stratum. These estimates are then summed across the CD4 count strata to obtain an
estimate of the total number of people with undiagnosed HIV within a broader CD4 count range.
The method requires knowledge of the CD4 count-specific rate of HIV-related symptoms of
sufficient severity to lead to presentation and HIV diagnosis. While the CD4 count-specific
rate of occurrence of AIDS is known, the CD4 count-specific rate of occurrence of such HIV-
related symptoms is less well described. There is evidence in the literature to suggest that the
rate of developing HIV-related symptoms is approximately two- to four-fold higher compared
to the rate of AIDS[14–16]. In observational cohorts of people with HIV who are being fol-
lowed for the presence of symptoms, more minor and less specific symptoms are likely to be
identified: these are symptoms that would not necessarily lead to testing and consequent diag-
nosis in an undiagnosed person. In the absence of CD4 count-specific estimates for the rate of
HIV-related symptoms, we therefore assume that the CD4 count-specific rates of HIV-related
symptoms are two-fold the CD4 count-specific rates of AIDS (see Table 1). The AIDS rates
were derived from data on the CASCADE collaboration of seroconverter cohorts [17,18]. They
were calculated by counting the number of AIDS events to have occurred within a period of
person-time, according to the most recent CD4 count measurement.
As rates of HIV-related symptoms at high CD4 counts (e.g. above 350 cells/mm3) are low,
applying this method to HIV diagnoses occurring at higher CD4 counts would involve multi-
plying up each surveillance case by a very large number (the inverse of the rate of HIV-related
symptoms) which may not produce stable estimates, albeit that this uncertainty is conveyed in
the 95% confidence intervals (see below). This method is therefore most appropriate for use in
estimating the numbers of undiagnosed people with HIV in the lower CD4 count range; i.e.
those in most need of ART (CD4 count below 200 cells/mm3).
This method is based on ‘London method 1’ in an editorial review on methods for estimating
the size of the undiagnosed population [2]. Here, we have revised the approach to be based on pres-
ence of HIV-related symptoms as a reason for the HIV test leading to diagnosis, rather than re-
stricting to AIDS itself. The reason for this is concern that people will often present with pre-AIDS
symptoms and so due to them being diagnosed and (unlike in the 1980s when the back-calculation
method was originally developed) treated, will not develop an AIDS-defining condition. Thus
AIDS (CDC-C events) alone is likely not sufficiently sensitive as the sentinel surveillance indicator.
Adjustment of the estimate
There may be diagnoses with symptoms where the CD4 count is missing. The estimate obtained
from this method should be divided by the proportion of all diagnoses with symptoms where the
CD4 count is known. This adjustment depends on the assumption that the probability that the
CD4 count is missing is independent of the actual CD4 count value, which may only be appropri-
ate if the proportion of diagnoses with missing CD4 count is sufficiently small.
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If there are known to be reporting delays or under-reporting of HIV cases with HIV-related
symptoms, then the estimates can further be adjusted. For example, if there is believed to be
3% of cases missing due to reporting delay or under-reporting, then the estimate can be further
multiplied by a factor of 1/0.97.
95% confidence intervals
To obtain 95% confidence intervals for the estimated number of people living with undiag-
nosed HIV, we suggest implementing a simple simulation method. There are two sources of
uncertainty for the estimate: the stochastic uncertainty concerning the CD4 count-specific rate
of symptoms and the stochastic uncertainty associated with the possibility that the observed
number of HIV diagnoses with HIV-related symptoms may not correspond to the expected
number based on the CD4 count-specific rate of symptoms. The rate of symptoms is assumed
to vary according to a Normal distribution (standard errors presented in Table 1). The ob-
served number of HIV diagnoses with HIV-related symptoms is assumed to vary according to
a Poisson distribution. We re-run the estimation procedure 10,000 times, each time sampling
the values of the rate of symptoms and the number of diagnoses with HIV related symptoms
from these distributions simultaneously. The 2.5th and 97.5th percentile of the resulting esti-
mated number with HIV are taken to be the limits of the 95% confidence interval.
Upper limit of estimate
The 95% confidence intervals described above convey uncertainty due to stochastic effects.
However, there are other sources of uncertainty. In particular, for some surveillance systems it
is possible that there is significant under-reporting of symptoms present at HIV diagnosis,
Fig 1. The basic concept underlying our method.
doi:10.1371/journal.pone.0121992.g001
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which would lead to under-estimation of the number living with undiagnosed HIV. We there-
fore also suggest calculation of an extreme upper limit for the number living with undiagnosed
HIV with low CD4 count which is based on the assumption that all HIV diagnoses were made
due to presence of symptoms.
Results
The method is applied to surveillance data on all HIV diagnoses with HIV-related symptoms
and CD4 count below 350 cells/mm3 in the country or region during the past year, grouped by
CD4 count strata. The method is demonstrated using data from 2011 on HIV diagnoses in the
Netherlands among men who have sex with men (MSM).
The calculation of the number with undiagnosed HIV and CD4 count below 350 cells/mm3
is presented in Table 1, showing a scenario in which there are a total of 63 HIV diagnoses with
symptoms during one year. The estimated number with undiagnosed HIV is then calculated
for each CD4 count stratum, for example 13/0.216 = 60 for CD4 count 150–199 cells/mm3.
Table 1. Example calculations.
CD4
count
cells/
mm3
Estimated
incidence rate
of HIV- related
symptoms per
person-year
Estimated
standard
error of HIV-
related
symptoms
Example calculation for point
estimate
Example calculation
for conﬁdence
interval
Example calculation for high
estimate
Number of
observed HIV
diagnoses with
HIV-related
symptoms in a
year
Point estimate for
the estimated
number of person
years lived with
undiagnosed HIV in
2011 in stratum
95% conﬁdence
interval for the
estimated number
of person years
lived with
undiagnosed HIV in
2011 in stratum
Number of
observed
HIV
diagnoses in
a year
High estimate for
the estimated
number of person
years lived with
undiagnosed HIV in
2011 in stratum
0–19 4.030 0.582 5 1 0–3 9 2
20–49 1.442 0.168 14 10 5–16 19 13
50–99 0.872 0.081 14 16 8–26 25 29
100–149 0.440 0.044 7 16 5–30 22 50
150–199 0.216 0.022 13 60 29–100 31 144
200–249 0.090 0.010 3 33a 0–80a 34 378a
250–299 0.076 0.007 3 39a 0–94a 41 539a
300–349 0.048 0.005 4 83a 18–176a 57 1188a
Total
(CD4
counts
0–200
cells/
mm3)
- - 53 103 51–165 106 238
Total
(CD4
counts
0–350
cells/
mm3)
- - 63 258a 159–415a 238 2343a
Estimates for the number of person-years lived with undiagnosed HIV among MSM in the Netherlands in 2011, rounded to the nearest integer (not
adjusted to take into account for missing CD4 counts or for reporting delay or under-reporting).
Note: Incidence rate and standard error of HIV-related symptoms obtained using data from the CASCADE cohort collaboration[16,17] (rate is two-fold the
incidence of AIDS).
aThese estimates should be interpreted with more caution due to the rates of HIV-related symptoms being much lower in the higher CD4 count ranges.
doi:10.1371/journal.pone.0121992.t001
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The overall estimate for the number of people living with undiagnosed HIV with CD4 count
<350 cells/mm3 is then the sum of these, 258.
The overall estimate may then be adjusted to take into account the overall proportion of di-
agnoses with symptoms where the CD4 count is missing. In the Dutch data, 7% of all diagnoses
with symptoms (including those with CD4 count at or above 350 cells/mm3) did not have a
CD4 count at or near the time of diagnosis, so then the modified estimate would be 258/
0.93 = 277. The estimate can be further adjusted to account for reporting delay or under-re-
porting, which is thought to be approximately 2% for the 2011 data. The estimate would then
be further modified to 277/0.98 = 283.
The 95% confidence intervals for each CD4 count strata are also presented in Table 1. In
this example, we used 10,000 simulation runs to obtain the limits. For the CD4 count stratum
150–199 cells/mm3, the 95% confidence interval is estimated to be 29–100 (95% confidence
interval is 32–110 after adjustment for the proportion with missing CD4 count and under-re-
porting). The point estimate and 95% confidence interval for the total number of people living
with undiagnosed HIV with CD4 count<200 and<350 cells/mm3 are 103 (51–165) and 258
(159–415) respectively. These are further adjusted to 113 (56–181) and 277 (171–455) respec-
tively (results not shown in Table 1) to account for the proportion with missing CD4 count
and under-reporting.
The extreme upper limit for the number with undiagnosed HIV and CD4 count below
350 cells/mm3, based on a situation in which all diagnoses of HIV are assumed to have resulted
from symptoms is also included in Table 1. This gives a much higher value of 2343 (adjusted
extreme upper limit is 2570).
Discussion
The presented method uses surveillance data on HIV diagnoses with HIV-related symptoms
to estimate the number of people living with undiagnosed HIV. The method allows estima-
tion of the number of people with undiagnosed HIV in any given low CD4 count range, for ex-
ample below 50 cells/mm3, where the need for ART is most urgent, or below 200 cells/mm3,
which is the consensus cut-off used to define advanced HIV disease [19]. Although the method
is most suitable for estimating the number with undiagnosed HIV with CD4 counts below
200 cells/mm3 in particular, it can also be used for estimating the number with undiagnosed
HIV and CD4 count between 200 and 350 cells/mm3, but should be interpreted with more cau-
tion due to the rate of developing HIV-related symptoms being much lower.
Our method is more straightforward to implement than existing back-calculation methods
and does not require the extensive data collection associated with methods based on prevalence
survey methods. Consequently this method could be applied in resource-limited settings if the
necessary data on all new diagnoses with HIV-related symptoms are collected for a period of
time. It could also be used as an additional alternative method in high-income settings where
such data already exist. The main advantage of our method is that only a limited period (e.g.
one year) of accurately collected surveillance data on the number of people newly diagnosed
with HIV who present with HIV-related symptoms, with their CD4 count, is required.
As the method works best when there are high levels of accurate ascertainment of HIV diag-
noses with symptoms, a potential source of bias is the possible under-diagnosis and under-re-
porting of such diagnoses. Although AIDS is often notified and diagnosed along with HIV,
audits have shown that there have been missed opportunities for HIV diagnoses where the pa-
tient presents with CDC-B and AIDS events[20]. On the other hand, the number of symptoms
which occur during primary HIV infection may increase with increased awareness and cam-
paigns over time, especially among certain high-risk groups such as MSM. Data on people with
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a diagnosis due to symptoms of primary HIV infection should not be included when using this
method, although their inclusion should not impact greatly on any estimates if these diagnoses
were in people with higher CD4 counts. Working to improve the completeness of data on the
presence of symptoms at diagnosis is thus an important priority for surveillance in countries
who wish to use this convenient method.
The method depends heavily on the availability of CD4 count at diagnosis, so although an
adjustment can be made if a small proportion of surveillance cases have missing CD4 count,
the method will be less reliable where a larger number of cases have no CD4 count data. This is
because if the assumption that those with missing CD4 count are representative of those with a
CD4 count is not met, the resultant bias is greater as the proportion with missing CD4 count
increases. It is conceivable that missing CD4 counts are more likely to be from individuals with
lower CD4 counts, because people with lower CD4 counts are those who are most ill and have
the highest risk of death, perhaps before CD4 counts can be measured. This will therefore po-
tentially lead to a lower estimate of the number of people with undiagnosed HIV. The extent to
which this bias may exist needs to be assessed in a sensitivity analysis, where people who died
rapidly such that a CD4 count could not be measured, are assumed to be in the lowest CD4
count category.
We recognise that the CD4 count-specific rate of HIV-related symptoms is derived some-
what arbitrarily by doubling the AIDS rate, although it was based on data from more than one
study of carefully followed cohorts [14–16], including a study of our own [14]. In choosing this
value of two-fold, we considered the possibility that the CD4 count-specific rate of AIDS in
people with undiagnosed HIV is actually higher than that observed in seroconverter cohorts, as
ART-naïve patients under care may have been treated with Pneumocystis jirovecii
pneumonia prophylaxis.
We did not attempt to stratify CD4 count-specific rates of HIV related symptoms according
to age or by other factors which are known to be associated with the progression of AIDS [21],
although such a development could be incorporated to refine the estimates.
We chose to demonstrate this method using HIV data from the Netherlands for 2011 because
it allowed us to compare our results with those estimated using an alternative method [22]. In
the comparison study, it was estimated that there were 140 (95% confidence interval: 120–160)
and 540 (470–600) MSM living with undiagnosed HIV with CD4 count<200 cells/mm3 and
<350 cells/mm3 respectively in 2011. Using our method, we found that the point estimate and
95% confidence interval for the number of people living with undiagnosed HIV with CD4
count<200 and<350 cells/mm3 were 113 (56–181) and 277 (171–455) respectively (after ad-
justment for the proportion with missing CD4 count at diagnosis and under-reporting). Con-
sidering the difficulties with estimating the size of a hidden population and the fact that the
estimates rely on different approaches and input data, the estimates are generally relatively
close and the two together helps to consolidate a feeling of understanding the true picture com-
pared with having either one alone available. It should be noted that since the 95% confidence
interval of our estimate only conveys uncertainty due to stochastic effects it is not necessarily
surprising that the alternative estimate (for the total number undiagnosed with CD4 count
<350 cells/mm3) does not lie within this interval. In addition, the alternative estimate pro-
duced using a back-calculation method, does not use data on all HIV-related symptoms at di-
agnosis, only AIDS. The alternative estimate was well within the extreme upper limit for our
estimate of 2570.
In conclusion, although like all approaches this method has limitations, it is straightforward
to implement soon after a good surveillance system is put in place and does not rely on histori-
cal data. As such, this method is important for prompting enhanced surveillance activity and
ultimately for establishing increased efforts to identify people with undiagnosed HIV,
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particularly those with low CD4 count, and for informing future delivery of ART. As a distinct-
ly different approach to existing methods, it can also be used in conjunction with others to
allow triangulation of estimates.
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